Ellerin Bruce E, Schneider Robert J, Stern Arnold, Toniolo Paolo G, Formenti Silvia C
Department of Radiation Oncology, New York University School of Medicine, New York, NY 10016-6497, USA.
J Am Coll Radiol. 2005 Nov;2(11):919-26. doi: 10.1016/j.jacr.2005.03.016.
Cancer research is a multibillion-dollar enterprise validated by the clinical trial process and increasingly defined by genomics. The continued success of the endeavor depends on the smooth functioning of the clinical trial system, which in turn depends on human subject participation. Yet human subject participation can exist only in an atmosphere of trust between research participants and research sponsors, and the advent of genomics has raised a multitude of ethical, legal, and social issues that threaten this trust. The authors examine 6 of these issues: (1) informed consent; (2) privacy, confidentiality, and family disclosure dilemmas; (3) property rights in genomic discoveries; (4) individual and institutional conflicts of interest; (5) insurance and employment issues; and (6) litigation under the federal False Claims Act. The authors conclude that failure to resolve these issues may lead to a sufficient impairment of trust in genomics-based clinical trials on the part of potential research participants that the clinical trial system may implode for lack of willing participants, thus threatening the future of cancer research.
癌症研究是一项价值数十亿美元的事业,已通过临床试验过程得到验证,并且越来越多地由基因组学来界定。这项事业的持续成功取决于临床试验系统的顺畅运作,而这又依赖于人类受试者的参与。然而,只有在研究参与者和研究资助者之间存在信任的氛围中,人类受试者的参与才有可能实现,而基因组学的出现引发了众多伦理、法律和社会问题,这些问题威胁到了这种信任。作者审视了其中6个问题:(1)知情同意;(2)隐私、保密和向家人披露信息的困境;(3)基因组发现中的产权;(4)个人和机构的利益冲突;(5)保险和就业问题;以及(6)根据联邦《虚假索赔法》提起的诉讼。作者得出结论,未能解决这些问题可能会导致潜在研究参与者对基于基因组学的临床试验的信任受到足够的损害,以至于临床试验系统可能因缺乏愿意参与的受试者而崩溃,从而威胁到癌症研究的未来。